Join at us the Annual Italy Investors Forum

Suva, the Swiss insurer that runs 99% of its roughly 60 billion franc portfolio actively, is now extending that conviction into a corner of the bond market built for it: the fund is buying collateralized loan obligations for the first time this year.

Christoph Bianchet, Suva’s chief investment officer, attributed the decision partly to the sector’s evolution since the 2008 financial crisis. “CLO 2.0 is a very different animal from the 1.0 type of vehicles that we experienced up until 2007,” said Bianchet. “The industry has learned a lot, has made it much more structured, safe and rules-based.”

The strategy is intended to complement the fund’s nearly fully active management approach. Bianchet, who joined Suva 13 years ago, said the conviction behind the portfolio has only grown over time, noting the fund has underperformed its strategic benchmark in just three of the 21 years it has been implementing the actively managed strategy.

Suva reported an investment return of 4.3% in 2025. While the return was down from 5.5% the prior year, it was still well above its 10-year average of 3.4%, according to a March 2026 press release. Its investment assets rose to 59 billion francs in 2025 from 57.9 billion francs the year before. As a not-for-profit, Suva’s finances and investments exist to meet its obligations to policyholders, with surplus investment returns ultimately returned to policyholders through lower premiums.

He also pointed to a potential regulatory tailwind: “With the change of regulation next year on the solvency regulation for the insurance company, maybe the demand is going to pick up.”

The European Union’s Solvency II regulation, which from January 2027 will lower capital charges for high-quality CLO tranches, making the asset class more capital-efficient for insurers to hold. Suva itself falls under the Swiss Solvency Test rather than Solvency II, but industry analysts expect Swiss insurers to move in the same direction as their European peers as demand and liquidity in the asset class increase.

Suva has established a target allocation of 2% of its portfolio to CLOs, translating to roughly 1.2 billion Swiss francs, Bianchet said. The new allocation is deliberately conservative: Suva is buying only triple-A-rated European CLO tranches for now.

“We’re not going into triple B, double B, single B tranches or equity for the time being. Maybe in a couple of years, when we’re feeling very comfortable with the space, we can talk about enlarging the mandate.”

Suva has built a list of pre-approved European CLO managers after conducting due diligence and is now deploying capital opportunistically rather than on a fixed schedule. “We’re looking at what’s coming to the market — is the spread that we earn attractive enough for us? Then we deploy, or we won’t.”

Bianchet said Suva is also working to close a gap in its direct real estate allocation after years in which the insurer’s overall balance sheet growth outpaced its property purchases. “We continuously  invested in direct real estate, but we couldn’t keep up,” he said. “Now the balance sheet growth has basically come to a halt. Now we try to catch up with the real estate quota.”

The portfolio remains concentrated in residential property, though Suva has occasionally financed single-tenant logistics buildings under long-term, triple-net lease structures when the risk-adjusted return justifies it.

Geographically, Bianchet said demand in residential real estate is pushing outward from Zurich into smaller Swiss cities such as Winterthur, Schaffhausen and Baden as tenants seek options within a roughly hour-long commute. Mortgage lending is another area of expansion, particularly through retail platforms that let Suva act purely as a financier across a large, diversified pool of individual borrowers. “That’s been very attractive for the last four years, five years, and we continue on that path.”

Bianchet was candid about the toll multi-year private equity underperformance has taken on institutional portfolios, including Suva’s. “I think that the big elephant in the room for many institutional investors is, of course, private equity,” he said, noting returns have lagged public markets for nearly four years.

“It’s almost impossible to double down in private equity because it’s such a long-term thing with a clear plan of deployment of capital,” he added. “We won’t accelerate the purchases right now. But we continue — we stick to our plan.”

He said Suva is not currently selling private equity positions in the secondary market, though it continues a modest, ongoing allocation to secondaries funds as part of its broader strategy.

Suva excludes only internationally banned weapons categories — such as cluster munitions, napalm and nuclear arms components — from its private equity portfolio, following exclusion guidelines set by SARI (Swiss Association for Responsible Investment). The industry body’s member institutions collectively represent roughly 300 billion francs in assets.

Beyond that, defense-sector investments remain permitted, said Bianchet, pointing to recent geopolitical conflicts as part of the reason Suva has not narrowed its defense-sector exposure further. On environmental, social and governance considerations more broadly, Bianchet said Suva’s board has been explicit that return cannot be sacrificed for ESG alignment. Still, the insurer is willing to help finance the energy transition where the risk-return profile holds up, he added, noting this is particularly important, given that Suva has committed to reaching net-zero greenhouse gas (GHG) financed emissions by 2050.